Effects of erythropoietin on fibroblast growth factor 23 in mice and humans

Nephrology Dialysis Transplantation

Volumn 34, Issue 12, 2019, Pages 2057-2065

  Hanudel, Mark R ^a   Eisenga, Michele F ^b   Rappaport, Maxime ^a   Chua, Kristine ^a   Qiao, Bo ^a   Jung, Grace ^a   Gabayan, Victoria ^a   Gales, Barbara ^a   Ramos, Georgina ^a   de Jong, Maarten A ^b   van Zanden, Jelmer J ^c   de Borst, Martin H ^b   Bakker, Stephan J L ^b   Nemeth, Elizabeta ^a   Salusky, Isidro B ^a   Gaillard, Carlo A J M ^d   Ganz, Tomas ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c MARTINI HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anemia; Chronic kidney disease; CKD MBD; Erythropoietin; Fibroblast growth factor 23

Indexed keywords

EPO PROTEIN, HUMAN; EPO PROTEIN, MOUSE; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23;

ANIMAL; BETA THALASSEMIA; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; KIDNEY TRANSPLANTATION; MALE; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; PROGNOSIS; TRANSGENIC MOUSE;

ANIMALS; BETA-THALASSEMIA; COHORT STUDIES; ERYTHROPOIETIN; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85075922042     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfy189     Document Type: Article

References (46)

1. Hsu CY, McCulloch CE, Curhan GC. Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2002; 13: 504-510
2. Isakova T, Wahl P, Vargas GS. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378
3. Farrow EG, Yu X, Summers LJ et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci USA 2011; 108: E1146-E1155
4. Clinkenbeard EL, Farrow EG, Summers LJ et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 2014; 29: 361-369
5. David V, Martin A, Isakova T et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 2016; 89: 135-146
6. Hanudel MR, Chua K, Rappaport M et al. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol 2016; 311: F1369-F1377
7. Clinkenbeard EL, Hanudel MR, Stayrook KR et al. Erythropoietin stimulates murine and human Fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 2017; 102: e427-e430
8. Rabadi S, Udo I, Leaf DE et al. Acute blood loss stimulates fibroblast growth factor 23 production. Am J Physiol Renal Physiol 2017; 314: F132-F139
9. Flamme I, Ellinghaus P, Urrego D et al. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase. PloS One 2017; 12: e0186979
10. Toro L, Barrientos V, Leon P. Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury. Kidney Int 2018; 93: 1131-1141
11. Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007; 18: 2600-2608
12. Isakova T, Xie H, Yang W et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439
13. Portale AA, Wolf MS, Messinger S et al. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol 2016; 11: 1989-1998
14. Mohanram A, Zhang Z, Shahinfar S et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-1138
15. Warady BA, Abraham AG, Schwartz GJ et al. Predictors of rapid progression of glomerular and nonglomerular kidney disease in children and adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort. Am J Kidney Dis 2015; 65: 878-888
16. Gutierrez OM, Januzzi JL, Isakova T et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009; 119: 2545-2552
17. Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393-4408
18. Mehta R, Cai X, Lee J et al. Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol 2016; 1: 548-556
19. Kovesdy CP, Trivedi BK, Kalantar-Zadeh K et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney Int 2006; 69: 560-564
20. Thorp ML, Johnson ES, Yang X et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology (Carlton) 2009; 14: 240-246
21. Baia LC, Humalda JK, Vervloet MG et al. Fibroblast growth factor 23 and cardiovascular mortality after kidney transplantation. Clin J Am Soc Nephrol 2013; 8: 1968-1978
22. Eisenga MF, van Londen M, Leaf DE et al. C-terminal fibroblast growth factor 23, Iron deficiency, and mortality in renal transplant recipients. J Am Soc Nephrol 2017; 28: 3639-3646
23. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798
24. Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014; 29: 2021-2028
25. Shimada T, Kakitani M, Yamazaki Y et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004; 113: 561-568
26. Larsson T, Nisbeth U, Ljunggren O et al. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-2279
27. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215
28. Portale AA, Wolf M, Juppner H et al. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 2014; 9: 344-353
29. Saito H, Maeda A, Ohtomo S et al. Circulating FGF-23 is regulated by 1al-pha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-2549
30. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006; 91: 3144-3149
31. Wesseling-Perry K, Pereira RC, Sahney S et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011; 79: 112-119
32. Lavi-Moshayoff V, Wasserman G, Meir T et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010; 299: F882-F889
33. Lopez I, Rodriguez-Ortiz ME, Almaden Y et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int 2011; 80: 475-482
34. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095
35. Artunc F, Risler T. Serum erythropoietin concentrations and responses to anaemia in patients with or without chronic kidney disease. Nephrol Dial Transplant 2007; 22: 2900-2908
36. Ruschitzka FT, Wenger RH, Stallmach T et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 2000; 97: 11609-11613
37. Tagliabracci VS, Engel JL, Wiley SE et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci USA 2014; 111: 5520-5525
38. Yamamoto H, Ramos-Molina B, Lick AN et al. Posttranslational processing of FGF23 in osteocytes during the osteoblast to osteocyte transition. Bone 2016; 84: 120-130
39. Goetz R, Nakada Y, Hu MC et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci USA 2010; 107: 407-412
40. Courbebaisse M, Mehel H, Petit-Hoang C et al. Carboxy-terminal fragment of fibroblast growth factor 23 induces heart hypertrophy in sickle cell disease. Haematologica 2017; 102: e33-e35
41. Frishberg Y, Ito N, Rinat C et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2006; 22: 235-242
42. Coe LM, Madathil SV, Casu C et al. FGF-23 is a negative regulator of prenatal and postnatal erythropoiesis. J Biol Chem 2014; 289: 9795-9810
43. Agoro R, Montagna A, Goetz R et al. Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia. FASEB J 2018. fj201700667R
44. Mehta R, Cai X, Hodakowski A et al. Fibroblast growth factor 23 and anemia in the Chronic Renal Insufficiency Cohort Study. Clin J Am Soc Nephrol 2017; 12: 1795-1803
45. Smith ER, Cai MM, McMahon LP et al. Biological variability of plasma intact and C-terminal FGF23 measurements. J Clin Endocrinol Metab 2012; 97: 3357-3365
46. Shimada T, Urakawa I, Isakova T et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab 2010; 95: 578-585